Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6556705 | 0.94 | ALDH1A1 (0.30) | ALDH1A1TSHR | |
| SCHEMBL139205 | 0.94 | ALDH1A1 (0.30) | ALDH1A1TSHR | |
| SCHEMBL18309137 | 0.87 | THRB (0.33) | — | |
| SCHEMBL18309144 | 0.87 | THRB (0.33) | — | |
| SCHEMBL25056718 | 0.85 | THRB (0.32) | — | |
| SCHEMBL14683257 | 0.85 | THRB (0.32) | — | |
| SCHEMBL14683260 | 0.85 | THRB (0.32) | — | |
| SCHEMBL26792741 | 0.85 | THRB (0.35) | — | |
| SCHEMBL26792715 | 0.85 | THRB (0.32) | — | |
| SCHEMBL10878266 | 0.85 | ALDH1A1 (0.35) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685863-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | MERCK PATENT GMBH (DE) | 2023-06-27 | — | — | US | disclosed |
| US-8987251-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140045817-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-8575145-B2 | Triazolopyridine compounds as PIM kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2013-11-05 | — | — | US | disclosed |
| WO-2012058591-A1 | BIOMATERIAL COMPOSITIONS | CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2012-05-03 | — | — | WO | disclosed |
| US-7709515-B2 | Compositions comprising ether compounds and pharmaceutical uses therefor | ESPERION THERAPEUTICS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685863-B2 | Polymerisable compounds and the use thereof in liquid-crystal displays | LPXN, VCL, LCP1 | ALDH1A1 3729/4885TSHR 4868/4885 |
| US-20140045817-A1 | TRIAZOLOPYRIDINE COMPOUNDS AS PIM KINASE INHIBITORS | PIM2, PIM1, PIM3 | ALDH1A1 1820/4885TSHR 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.